Adcetris 50mg Injection is used for certain CD30-positive blood cancers, including:

• Previously untreated stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy.

• Classical Hodgkin lymphoma at high risk of relapse or progression as consolidation treatment after autologous stem cell transplantation.

• Relapsed classical Hodgkin lymphoma after certain previous treatments.

• Previously untreated systemic anaplastic large cell lymphoma (sALCL) and certain CD30-expressing peripheral T-cell lymphomas, in combination with chemotherapy.

• Relapsed systemic anaplastic large cell lymphoma.

• Relapsed primary cutaneous anaplastic large cell lymphoma and CD30-expressing mycosis fungoides after previous systemic treatment.

The exact treatment regimen depends on the type and stage of lymphoma and previous therapy.

Adcetris contains Brentuximab Vedotin, an antibody-drug conjugate (ADC). An ADC combines a targeted antibody with a cancer-killing component.

Brentuximab targets CD30, a protein found on the surface of certain lymphoma cells. After entering the cancer cell, the drug component is released and interferes with structures needed for cell division, leading to cancer cell death.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and herbal supplements you take.

• Bleomycin: Adcetris must not be given with Bleomycin because the combination can cause serious lung toxicity.

• Strong CYP3A inhibitors: Medicines such as certain azole antifungals may increase exposure to the active component of Brentuximab Vedotin and may increase side effects.

• Chemotherapy: Adcetris is used with specific chemotherapy combinations for some indications. Your oncology team will determine the appropriate regimen.

• Other medicines: Tell your doctor about all medicines you take before starting treatment.

• Store Adcetris 50mg Injection in a refrigerator at 2°C to 8°C.

• Do not freeze.

• Protect the vial from light.

• Reconstituted and diluted solutions should be prepared and stored according to the product instructions by the healthcare team.

• Keep the unopened product out of the sight and reach of children.

Adcetris 50mg Injection is administered as an intravenous infusion over approximately 30 minutes by a healthcare professional.

The dose depends on the cancer being treated and may be calculated according to body weight. Different indications use different dosing schedules, such as every 2 or 3 weeks.

Do not self-administer Adcetris. Your doctor may delay, reduce or stop treatment depending on your response and side effects.

Common side effects:

• Tiredness

• Nausea

• Fever

• Diarrhoea

• Vomiting

• Reduced blood cell counts

• Peripheral neuropathy

• Headache

• Rash

• Infusion-related reactions

Serious side effects:

• Severe peripheral neuropathy

• Serious infections

• Progressive multifocal leukoencephalopathy

• Severe liver injury

• Serious lung problems

• Tumour lysis syndrome

• Severe infusion-related reactions

• Pancreatitis

• Severe skin reactions

Seek medical attention promptly for breathing difficulty, severe weakness, confusion, yellowing of the skin or eyes, severe abdominal pain or new neurological symptoms.

• Adcetris should be administered only by a healthcare professional experienced in cancer treatment.

• Tell your doctor if you are taking Bleomycin or medicines used to treat infections.

• Report numbness, tingling, burning or weakness in the hands or feet early because these may indicate peripheral neuropathy.

• Keep scheduled blood tests to monitor blood cell counts and liver function.

• Report fever or other signs of infection promptly.

• Do not receive live vaccines without discussing them with your doctor.